Endocrine Insider
January 20, 2010

(See Full Issue)

The Endocrine Society released a statement for members this week in response to the American Diabetes Association’s (ADA) new clinical practice recommendation supporting the use of hemoglobin A1C (A1C) as an appropriate diagnostic tool for diabetes and pre-diabetes. In its recommendations, the ADA suggests that A1C can be used as a diagnostic tool without the need for other confirmatory fasting plasma glucose and oral glucose tolerance tests, a clinical development that is expected to have a wide-reaching impact on the diabetes community and the public.

The Endocrine Society supports the ADA recommendation for use of A1C as an option to diagnose diabetes; however, there are certain caveats that must be understood by clinicians and the public as this diagnostic test increases in use. The Society’s statement detailing these caveats may be viewed at here.   

If you have any questions, please contact Lisa Marlow, Manager, Government Affairs, at lmarlow@endo-society.org.